全文获取类型
收费全文 | 28082篇 |
免费 | 2003篇 |
国内免费 | 57篇 |
专业分类
耳鼻咽喉 | 105篇 |
儿科学 | 759篇 |
妇产科学 | 801篇 |
基础医学 | 4332篇 |
口腔科学 | 139篇 |
临床医学 | 2491篇 |
内科学 | 7640篇 |
皮肤病学 | 278篇 |
神经病学 | 2166篇 |
特种医学 | 1098篇 |
外科学 | 4272篇 |
综合类 | 124篇 |
现状与发展 | 1篇 |
一般理论 | 45篇 |
预防医学 | 2177篇 |
眼科学 | 215篇 |
药学 | 1615篇 |
中国医学 | 16篇 |
肿瘤学 | 1868篇 |
出版年
2024年 | 16篇 |
2023年 | 733篇 |
2022年 | 1017篇 |
2021年 | 1314篇 |
2020年 | 1205篇 |
2019年 | 791篇 |
2018年 | 962篇 |
2017年 | 934篇 |
2016年 | 877篇 |
2015年 | 969篇 |
2014年 | 1660篇 |
2013年 | 1523篇 |
2012年 | 1415篇 |
2011年 | 1450篇 |
2010年 | 1344篇 |
2009年 | 1359篇 |
2008年 | 1267篇 |
2007年 | 1181篇 |
2006年 | 1045篇 |
2005年 | 1041篇 |
2004年 | 1083篇 |
2003年 | 1014篇 |
2002年 | 1016篇 |
2001年 | 1106篇 |
2000年 | 961篇 |
1999年 | 882篇 |
1998年 | 425篇 |
1997年 | 259篇 |
1996年 | 192篇 |
1995年 | 151篇 |
1994年 | 110篇 |
1993年 | 95篇 |
1992年 | 125篇 |
1991年 | 96篇 |
1990年 | 88篇 |
1989年 | 71篇 |
1988年 | 71篇 |
1987年 | 41篇 |
1985年 | 31篇 |
1984年 | 24篇 |
1983年 | 20篇 |
1982年 | 21篇 |
1981年 | 24篇 |
1980年 | 18篇 |
1979年 | 12篇 |
1978年 | 13篇 |
1977年 | 12篇 |
1975年 | 14篇 |
1974年 | 12篇 |
1973年 | 13篇 |
排序方式: 共有10000条查询结果,搜索用时 171 毫秒
81.
82.
83.
《The Canadian journal of cardiology》2019,35(9):1097-1105
BackgroundAcute heart failure (HF) patients with renal insufficiency and risk factors for diuretic resistance may be most likely to derive incremental improvement in congestion with the addition of spironolactone.MethodsThe Aldosterone Targeted Neurohormonal Combined with Natriuresis Therapy in Heart Failure (ATHENA-HF) trial randomized 360 acute HF patients with reduced or preserved ejection fraction to spironolactone 100 mg daily or usual care for 96 hours. The current analysis assessed the effects of study therapy within tertiles of baseline estimated glomerular filtration rate (eGFR) and subgroups at heightened risk for diuretic resistance.ResultsAcross eGFR tertiles, there was no incremental benefit of high-dose spironolactone on any efficacy endpoint, including changes in log N-terminal pro-B-type natriuretic peptide and signs and symptoms of congestion (all P for interaction ≥ 0.06). High-dose spironolactone had no significant effect on N-terminal pro-B-type natriuretic peptide reduction regardless of blood pressure, diabetes mellitus status, and loop diuretic dose (all P for interaction ≥ 0.38). In-hospital changes in serum potassium and creatinine were similar between treatment groups for all GFR tertiles (all P for interaction ≥ 0.18). Rates of inpatient worsening HF, 30-day worsening HF, and 60-day all-cause mortality were numerically higher among patients with lower baseline eGFR, but relative effects of study treatment did not differ with renal function (all P for interaction ≥ 0.27).ConclusionsHigh-dose spironolactone did not improve congestion over usual care among patients with acute HF, irrespective of renal function and risk factors for diuretic resistance. In-hospital initiation or continuation of spironolactone was safe during the inpatient stay, even when administered at high doses to patients with moderate renal dysfunction. 相似文献
84.
《Lancet neurology》2020,19(11):940-950
85.
86.
M A Birrell K McCluskie E Hardaker R Knowles M G Belvisi 《The European respiratory journal》2006,28(6):1236-1244
There is a great deal of interest in developing less invasive markers for monitoring airway inflammation and the effect of possible novel anti-inflammatory therapies that may take time to impact on disease pathology. Exhaled nitric oxide (eNO) has been shown to be a reproducible, noninvasive indicator of the inflammatory status of the airway in the clinic. The aim of the present study was to determine the usefulness of measuring eNO as a marker of the anti-inflammatory impact of glucocorticoid and an inhibitor of kappaB kinase-2 (IKK-2) inhibitor 2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide (TPCA-1), in a pre-clinical model of airway inflammation. Rats were given vehicle, budesonide or TPCA-1 prior to exposure to lipopolysaccharide, previously shown to induce an increase in eNO and airway neutrophilia/eosinophilia. Comparison of the effect of the two compounds on inflammatory components demonstrated a significant correlation between the impact on eNO and inflammatory cell burden in the airway. The current study demonstrates the usefulness of profiling potential disease-modifying therapies on exhaled nitric oxide levels and the way in which an effect on this noninvasive biomarker relates to effects on pathological parameters such as lung cellularity. Information from studies such as the current one would suggest that the measurement of exhaled nitric oxide has potential for monitoring inflammatory status in lung tissue. 相似文献
87.
88.
89.
90.
S Chinn S H Downs J M Anto M W Gerbase B Leynaert R de Marco C Janson D Jarvis N Künzli J Sunyer C Svanes E Zemp U Ackermann-Liebrich P Burney 《The European respiratory journal》2006,28(4):763-771
The incidence of asthma has been reported to be associated with obesity. An alternative analysis, of net change in prevalence, does not require exclusion of those with asthma at baseline. Follow-up data were obtained from 9,552 participants in the European Community Respiratory Health Survey and the Swiss cohort Study on Air Pollution and Lung Disease in Adults. Incidence of asthma was analysed by proportional hazards regression, and net changes in symptoms and asthma status by generalised estimating equations, by obesity group. Incidence and net change in ever having had asthma were greater in females than in males, and in participants who remained obese compared with those who were never obese (hazard ratio 2.00, 95% confidence interval 1.25-3.20; excess net change 2.8%, 0.4-5.3% per 10 yrs). The effect of being obese on net change in diagnosed asthma was greater in females than in males, but for net change in wheeze without a cold it was greater in males. The present results are consistent with asthma being more frequently diagnosed in females, especially obese females. These findings may help to explain the reports of a stronger association between asthma and obesity in females than in males. 相似文献